Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma

Gastroenterology Clinics of North America

Volumn 44, Issue 4, 2015, Pages 761-773

  Tholey, Danielle M ^a   Ahn, Joseph ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Direct acting antivirals; Hepatitis C virus; Hepatocellular carcinoma; Liver cancer

Indexed keywords

ANTIVIRUS AGENT; CORE PROTEIN; INTERFERON; MICRORNA; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; DRUG RESPONSE; ELASTOGRAPHY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFESTYLE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; NONHUMAN; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; INCIDENCE; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOGENICITY; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84947615771     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.07.005     Document Type: Review

References (55)

1. Bosetti C., Turati F., La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014, 28(5):753-770.
2. Gomaa A.I., Khan S.A., Toledano M.B., et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008, 14(27):4300-4308.
3. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138(2):513-521. 521.e1-6.
4. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142(6):1264-1273.e1.
5. Huang Y.T., Jen C.L., Yang H.I., et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011, 29(27):3643-3650.
6. Altekruse S.F., Henley S.J., Cucinelli J.E., et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014, 109(4):542-553.
7. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
8. Sievert W., Altraif I., Razavi H.A., et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(Suppl 2):61-80.
9. El-Serag H.B., Kramer J., Duan Z., et al. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol 2014, 109(9):1427-1435.
10. Davila J.A., Morgan R.O., Shaib Y., et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54(4):533-539.
11. Khattab M.A., Eslam M., Mousa Y.I., et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol 2012, 11(4):487-494.
12. N'Kontchou G., Paries J., Htar M.T., et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006, 4(8):1062-1068.
13. Kruse R.L., Kramer J.R., Tyson G.L., et al. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology 2014, 60(6):1871-1878.
14. Ioannou G.N., Bryson C.L., Weiss N.S., et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013, 57(1):249-257.
15. Saab S., Mallam D., Cox G.A., et al. Impact of coffee on liver diseases: a systematic review. Liver Int 2014, 34(4):495-504.
16. Wakai K., Kurozawa Y., Shibata A., et al. Liver cancer risk, coffee, and hepatitis C virus infection: a nested case-control study in Japan. Br J Cancer 2007, 97(3):426-428.
17. Bravi F., Bosetti C., Tavani A., et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013, 11(11):1413-1421.e1.
18. Kurozawa Y., Ogimoto I., Shibata A., et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005, 93(5):607-610.
19. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75(3):347-354.
20. Chuang S.C., Lee Y.C., Hashibe M., et al. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010, 19(5):1261-1268.
21. Kanwal F., Kramer J.R., Ilyas J., et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV. Hepatology 2014, 60(1):98-105.
22. Alkofer B., Lepennec V., Chiche L. Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg 2011, 148(1):3-11.
23. Lemon S.M., McGivern D.R. Is hepatitis C virus carcinogenic?. Gastroenterology 2012, 142(6):1274-1278.
24. Kannan R.P., Hensley L.L., Evers L.E., et al. Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol 2011, 85(16):7989-8001.
25. Walters K.A., Syder A.J., Lederer S.L., et al. Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog 2009, 5(1):e1000269.
26. Park C.Y., Choi S.H., Kang S.M., et al. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J Hepatol 2009, 51(5):853-864.
27. Li Y., Boehning D.F., Qian T., et al. Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J 2007, 21(10):2474-2485.
28. Qiu W., Wang X., Leibowitz B., et al. PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology 2011, 54(4):1249-1258.
29. Meng F., Henson R., Wehbe-Janek H., et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133(2):647-658.
30. Morgan R.L., Baack B., Smith B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013, 158(5 Pt 1):329-337.
31. Singal A.G., Volk M.L., Jensen D., et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8(3):280-288. 288.e1.
32. Omland L.H., Krarup H., Jepsen P., et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010, 53(1):36-42.
33. George S.L., Bacon B.R., Brunt E.M., et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49(3):729-738.
34. Hikmet A., Macit S., Ersin A., et al. Efficacy of pegylated interferon alpha and ribavirin treatment on risk of hepatocellular carcinoma in patients with chronic hepatitis C a prospective study. Hepatol Int 2015, 9(Supp 1):S75. [APSAL abstract: 2183].
35. Ikeda M., Fujiyama S., Tanaka M., et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005, 40(2):148-156.
36. Toyoda H., Kumada T., Tada T., et al. Risk factors of HCC development in non-cirrhotic patients with sustained virologic response for chronic HCV infection. J Gastroenterol Hepatol 2015, 30(7):1183-1189.
37. Veldt B.J., Heathcote E.J., Wedemeyer H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147(10):677-684.
38. Manns M., Pol S., Jacobson I.M., et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014, 384(9954):1597-1605.
39. Lawitz E., Sulkowski M.S., Ghalib R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, 384(9956):1756-1765.
40. Makiyama A., Itoh Y., Kasahara A., et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004, 101(7):1616-1622.
41. Bruix J., Sherman M., American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
42. Huang Y., de Boer W.B., Adams L.A., et al. Clinical outcomes of chronic hepatitis C patients related to baseline liver fibrosis stage: a hospital-based linkage study. Intern Med J 2015, 45(1):48-54.
43. European Association For the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012, 56(4):908-943.
44. Lewis S., Roayaie S., Ward S.C., et al. Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. AJR Am J Roentgenol 2013, 200(6):W610-W616.
45. Singal A.G., Li X., Tiro J., et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015, 128(1):90.e1-90.e7.
46. El-Serag H.B., Kramer J.R., Chen G.J., et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 2011, 60(7):992-997.
47. Masuzaki R., Tateishi R., Yoshida H., et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009, 49(6):1954-1961.
48. Canavan C., Eisenburg J., Meng L., et al. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013, 58(9):2691-2704.
49. Bourcier V., Winnock M., Ait Ahmed M., et al. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol 2012, 36(3):214-221.
50. Puoti M., Bruno R., Soriano V., et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004, 18(17):2285-2293.
51. Hu Z., Li Z., Xiang J., et al. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci 2014, 59(12):3062-3072.
52. Bozorgzadeh A., Orloff M., Abt P., et al. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl 2007, 13(6):807-813.
53. Dumitra S., Alabbad S.I., Barkun J.S., et al. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. HPB (Oxford) 2013, 15(9):724-731.
54. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11):693-699.
55. Crosbie O.M., Alexander G.J. Liver transplantation for hepatitis C virus related cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000, 14(2):307-325.